Surreal illustration of a healthy eye intertwined with molecular strands, symbolizing corneal neovascularization treatment.

Beyond Bevacizumab: Exploring New Avenues in Corneal Neovascularization Treatment

Lena Voss in Health & Wellness August 2025 • 4 min read.

"Can Sunitinib and miRNA Levels Offer a Breakthrough in Eye Care?"

The cornea, the eye's outermost layer, plays a vital role in vision by refracting light and protecting the inner structures. Its transparency, maintained by a lack of blood vessels, is crucial for clear sight. Corneal neovascularization (CNV), the abnormal growth of new blood vessels into the cornea, can compromise this transparency, leading to visual impairment and blindness. This condition affects millions worldwide, highlighting the urgent need for effective treatments.

Current treatments for CNV often involve anti-VEGF (vascular endothelial growth factor) therapies, which aim to block the signals that stimulate blood vessel growth. Bevacizumab, a commonly used anti-VEGF agent, has shown promise in reducing CNV. However, its effectiveness can vary, and alternative strategies are continuously being explored. Researchers are now investigating new approaches, including the use of sunitinib, another angiogenesis inhibitor, and the modulation of microRNAs (miRNAs), small molecules that regulate gene expression.

This article delves into a recent study that examines the effects of sunitinib and bevacizumab on VEGF and miRNA levels in corneal neovascularization. By understanding these effects, scientists hope to develop more targeted and effective treatments for CNV, ultimately preserving vision and improving the quality of life for those affected.

Sunitinib and Bevacizumab's Impact on Corneal Neovascularization: What the Study Reveals

Surreal illustration of a healthy eye intertwined with molecular strands, symbolizing corneal neovascularization treatment.

A recent study investigated the effects of sunitinib and bevacizumab on corneal neovascularization in rats. The researchers induced CNV by applying silver nitrate to the corneas of the rats, then divided them into four groups:

Group 1 (Sunitinib): Received 0.5mg/ml sunitinib eye drops twice daily.

Group 2 (Bevacizumab): Received 5mg/ml bevacizumab eye drops twice daily.
Group 3 (Control): Received normal saline eye drops twice daily.
Group 4 (Vehicle): Received 1% DMSO eye drops twice daily.

After two weeks, the corneas were evaluated for vascularization, and the expression levels of VEGF-A, VEGFR-2, and several miRNAs were measured. The results showed that both sunitinib and bevacizumab reduced corneal neovascularization compared to the control and DMSO groups. Additionally, VEGF-A and VEGFR-2 expression were downregulated in the sunitinib and bevacizumab groups.

The Future of CNV Treatment: A Glimpse of Hope

The study's findings suggest that both bevacizumab and sunitinib can effectively reduce corneal neovascularization by downregulating VEGF and VEGFR-2 expression and modulating miRNA levels. These results provide valuable insights into the potential of these agents for treating CNV. However, further research is needed to fully understand the mechanisms involved and to optimize treatment strategies. Future studies should focus on identifying the specific genes targeted by the modulated miRNAs and exploring the long-term effects of these treatments. With continued investigation, these findings could pave the way for more effective and targeted therapies for corneal neovascularization, offering hope for preserving vision and improving the quality of life for those affected.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

Everything You Need To Know

What exactly is corneal neovascularization, and why is it a problem?

Corneal neovascularization (CNV) is the abnormal growth of new blood vessels into the cornea. This is problematic because the cornea's transparency, which is vital for clear vision, is maintained by the absence of blood vessels. When CNV occurs, this transparency is compromised, potentially leading to visual impairment and even blindness. Treatments aim to stop or reduce this blood vessel growth to preserve the cornea's clarity and function.

What are the current treatments available for corneal neovascularization?

Current treatments for corneal neovascularization often use anti-VEGF (vascular endothelial growth factor) therapies. Bevacizumab is a common anti-VEGF agent that works by blocking the signals that stimulate blood vessel growth. While Bevacizumab has shown promise, its effectiveness can vary, so researchers are exploring other options, such as sunitinib and methods to control microRNAs (miRNAs).

What is sunitinib, and how might it help with corneal neovascularization?

Sunitinib is another angiogenesis inhibitor, meaning it also works to prevent the growth of new blood vessels, similar to Bevacizumab. Studies are exploring Sunitinib's potential as an alternative or supplementary treatment for corneal neovascularization. It can reduce corneal neovascularization by downregulating VEGF and VEGFR-2 expression and modulating miRNA levels. Investigating Sunitinib is important for patients who do not respond well to Bevacizumab.

What are microRNAs, and how could they be used to treat corneal neovascularization?

MicroRNAs (miRNAs) are small molecules that play a crucial role in regulating gene expression. By influencing which genes are turned on or off, miRNAs can affect various biological processes, including blood vessel growth. Modulating miRNA levels could potentially help control corneal neovascularization. Researchers aim to identify specific miRNAs that promote or inhibit CNV, and then develop therapies to alter their levels, leading to more targeted treatments.

What did the study reveal about using sunitinib and bevacizumab together for corneal neovascularization?

A recent study investigated the effects of both sunitinib and bevacizumab on corneal neovascularization (CNV) in rats, focusing on VEGF and miRNA levels. The study found that both Sunitinib and Bevacizumab reduced CNV and lowered the expression of VEGF-A and VEGFR-2. This shows that both agents can modify the key molecular signals involved in CNV. This research helps provide a basis for developing more effective treatments for CNV.